Introduction
COVID-19 is a worldwide pandemic disease that caused respiratory
symptoms and severe systemic complications. In August 2021, the FDA
approved the first mRNA COVID-19 vaccine known as the Pfizer-BioNTech
COVID-19 Vaccine (ComirnatyTM) to prevent COVID-19 in
adult patients. Common reported cutaneous adverse reactions were delayed
large local reactions, swelling, urticarial rash, and flare existing
dermatologic conditions.2,3,4,5 However, only a few
cases of the subepidermal blistering eruption were
reported6.